Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PGEN – Precigen, Inc.

Precigen, Inc.
PGEN
$1.67
Name : Precigen, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $492,950,592.00
EPSttm : -0.55
finviz dynamic chart for PGEN
Precigen, Inc.
$1.67
2.34%
$0.04

Float Short %

19.44

Margin Of Safety %

Put/Call OI Ratio

0.32

EPS Next Q Diff

-0.01

EPS Last/This Y

0.1

EPS This/Next Y

0.42

Price

1.67

Target Price

6

Analyst Recom

2

Performance Q

7.74

Relative Volume

0.91

Beta

1.87

Ticker: PGEN




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04PGEN1.620.380.0549044
2025-07-07PGEN1.590.380.0849182
2025-07-08PGEN1.70.380.0549376
2025-07-09PGEN1.90.370.0750657
2025-07-10PGEN1.9050.310.0255925
2025-07-11PGEN1.820.310.1156357
2025-07-14PGEN1.9550.310.0556510
2025-07-15PGEN1.8450.312.0456541
2025-07-16PGEN1.840.310.2256727
2025-07-17PGEN1.830.293.4158553
2025-07-18PGEN1.7550.330.0060300
2025-07-21PGEN1.840.370.0049862
2025-07-22PGEN1.5150.371.1450693
2025-07-23PGEN1.650.230.5743921
2025-07-24PGEN1.60.270.6848348
2025-07-25PGEN1.580.304.8152271
2025-07-28PGEN1.5850.340.0155544
2025-07-29PGEN1.580.332.5756712
2025-07-30PGEN1.730.4010.9660794
2025-07-31PGEN1.7050.330.1457714
2025-08-01PGEN1.6750.320.0258633
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04PGEN1.6219.9- -0.37
2025-07-07PGEN1.6019.9- -0.37
2025-07-08PGEN1.7019.9- -0.37
2025-07-09PGEN1.9019.9- -0.37
2025-07-10PGEN1.9119.9- -0.37
2025-07-11PGEN1.8319.9- -0.37
2025-07-14PGEN1.9519.9- -0.37
2025-07-15PGEN1.8519.9- -0.37
2025-07-16PGEN1.8419.9- -0.37
2025-07-17PGEN1.8219.9- -0.37
2025-07-18PGEN1.7619.9- -0.37
2025-07-21PGEN1.8419.9- -0.37
2025-07-22PGEN1.5119.9- -0.37
2025-07-23PGEN1.6619.9- -0.37
2025-07-24PGEN1.6019.9- -0.37
2025-07-25PGEN1.5719.9- -0.37
2025-07-28PGEN1.5819.9- -0.37
2025-07-29PGEN1.5719.9- -0.37
2025-07-30PGEN1.7319.9- -0.37
2025-07-31PGEN1.7119.9- -0.37
2025-08-01PGEN1.6719.9- -0.37
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04PGEN0.006.0618.64
2025-07-07PGEN0.007.0818.64
2025-07-08PGEN0.007.0818.64
2025-07-09PGEN0.007.0818.64
2025-07-10PGEN0.007.0818.64
2025-07-11PGEN0.007.0819.85
2025-07-14PGEN0.007.1719.85
2025-07-15PGEN0.007.1719.85
2025-07-16PGEN0.007.1719.85
2025-07-17PGEN0.007.1719.85
2025-07-18PGEN0.007.1719.85
2025-07-21PGEN0.007.1419.85
2025-07-22PGEN0.007.1419.85
2025-07-23PGEN0.007.1419.85
2025-07-24PGEN0.007.1419.85
2025-07-25PGEN0.007.1419.44
2025-07-28PGEN0.007.3519.44
2025-07-29PGEN0.007.3519.44
2025-07-30PGEN0.007.3519.44
2025-07-31PGEN0.007.3519.44
2025-08-01PGEN0.007.3519.44
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.07

Avg. EPS Est. Current Quarter

-0.08

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

Institutional Transactions

7.35

Beta

1.87

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

3

Growth Score

33

Sentiment Score

78

Actual DrawDown %

85

Max Drawdown 5-Year %

-93.8

Target Price

6

P/E

Forward P/E

PEG

P/S

117.37

P/B

P/Free Cash Flow

EPS

-0.57

Average EPS Est. Cur. Y​

-0.37

EPS Next Y. (Est.)

0.05

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3728.87

Relative Volume

0.91

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Precigen, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 143
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
stock quote shares PGEN – Precigen, Inc. Stock Price stock today
news today PGEN – Precigen, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PGEN – Precigen, Inc. yahoo finance google finance
stock history PGEN – Precigen, Inc. invest stock market
stock prices PGEN premarket after hours
ticker PGEN fair value insiders trading